Project Grant R01AI195578
Award Date 8/19/26
Completion Date 7/31/31
Dollars Obligated $726K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $250,682 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of nuclear paraspeckles in regulating herpes simplex virus type 1 (HSV-1) infection in neurons. The research examines how nuclear speckles and paraspeckles—subnuclear ribonucleoprotein structures involved in gene expression and RNA processing—modulate HSV-1 replication and...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Princeton University $133,600 on September 24, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate virus-induced chaperone enriched (VICE) domain functions during herpes simplex virus type-1 infection. The award funds research examining how HSV-1 remodels the host cell nucleus by requisitioning histones, RNA polymerases, and ribosomal machinery. The recipient's prior work...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $480,000 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the molecular mechanisms underlying anti-aquaporin-4 responses in neuromyelitis optica spectrum disorder (NMOSD). The research addresses the autoimmune pathogenesis of NMOSD, a severe central nervous system disease driven by T cell and autoantibody responses against aquaporin-4 on...
- The National Institute of Allergy and Infectious Diseases awarded Trustees of Dartmouth College $149,190 on January 29, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to improve herpes simplex virus vaccination efficacy and neonatal infection outcomes. The research investigates how age impacts murine immunization efficacy and the neonatal response to viral challenge, with the hypothesis that the type and timeline of neonatal, juvenile, adolescent, and maternal...
- The National Institute of Allergy and Infectious Diseases awarded Louisiana State University Health Sciences Center-Shreveport $660,723 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of Z-form nucleic acid binding protein 1 (ZBP1) in controlling herpes simplex virus type 1 (HSV-1) pathogenesis. The research will identify Z-RNA ligands that activate ZBP1 during HSV-1 infection and determine how these ligands form in infected...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $231,000 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify, characterize, and develop human monoclonal antibodies whose primary protective mechanism is antibody-dependent cellular cytotoxicity (ADCC) for treatment and prevention of genital, neonatal, and recurrent herpes simplex virus (HSV) infections. The research builds on preclinical mouse...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $796,976 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a once-daily ocular nanoformulation of BX795, a non-nucleoside antiviral drug for herpes simplex virus keratitis therapy. HSV-1 keratitis causes corneal blindness globally, and current nucleoside antiherpetic treatments administered orally or topically prove insufficient, with emerging...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Connecticut Health Center $263,375 on April 20, 2026 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antiviral therapies targeting herpes simplex virus alkaline nuclease. The funded research addresses drug-resistant HSV strains by identifying the HSV alkaline nuclease (encoded by the UL12 gene) as a novel target for antiviral drug discovery. Existing therapies rely on...
- The National Institute of Allergy and Infectious Diseases awarded Northern Illinois University $147,766 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2026. The award funds research investigating how geminivirus viral RNA silencing suppressors (AC2/C2 proteins) subvert the SNRK1/autophagy pathway to suppress host plant antiviral immune responses. The research addresses geminivirus crop disease control by examining defense-counterdefense interactions at...